Impax Laboratories, Inc. (NASDAQ:IPXL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Meeting of Stockholders on May 16, 2017. The final results of the
voting for each matter submitted to a vote of stockholders at the
meeting are as follows:
serve a term of one year and until his or her successor has been
elected and qualified or until the directors earlier death,
resignation or removal or service as a director otherwise
concludes.
|
Nominee
|
Votes For
|
Against
|
Abstentions
|
Broker Non-Votes
|
|
Leslie Z. Benet, Ph.D.
|
52,569,502
|
483,600
|
903,497
|
7,714,212
|
|
Richard A. Bierly
|
52,672,895
|
164,483
|
1,119,221
|
7,714,212
|
|
Paul M. Bisaro
|
51,960,297
|
1,039,297
|
957,005
|
7,714,212
|
|
J. Kevin Buchi
|
52,810,869
|
210,492
|
935,238
|
7,714,212
|
|
Robert L. Burr
|
49,299,419
|
3,621,010
|
1,036,170
|
7,714,212
|
|
Allen Chao, Ph.D.
|
49,137,892
|
3,799,919
|
1,018,788
|
7,714,212
|
|
Mary K. Pendergast, J.D.
|
49,206,608
|
3,718,205
|
1,031,786
|
7,714,212
|
|
Peter R. Terreri
|
49,093,330
|
3,853,424
|
1,009,845
|
7,714,212
|
|
Janet S. Vergis
|
52,586,198
|
291,123
|
1,079,278
|
7,714,212
|
Stock Purchase Plan
Companys Non-Qualified Employee Stock Purchase Plan to, among
other items, increase the aggregate number of shares of the
Companys common stock that may be reserved under such plan by
1,500,000 shares was approved.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
52,722,477
|
197,943
|
1,036,179
|
7,714,212
|
Equity Incentive Plan
the Companys 2002 Equity Incentive Plan to, among other items,
increase the aggregate number of shares of the Companys common
stock that may be issued under such plan by 2,100,000 shares was
approved.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
48,079,359
|
1,496,982
|
4,380,258
|
7,714,212
|
compensation of the Companys named executive officers was
approved.
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
51,538,733
|
1,335,218
|
1,082,648
|
7,714,212
|
frequency of named executive officer compensation votes of one
year is approved.
|
One Year
|
Two Years
|
Three Years
|
Abstentions
|
Broker Non-Votes
|
|
39,946,915
|
103,805
|
12,872,721
|
1,033,158
|
7,714,212
|
Public Accounting Firm
public accounting firm for the fiscal year ending December 31,
2017. >
|
Votes For
|
Votes Against
|
Abstentions
|
Broker Non-Votes
|
|
60,021,800
|
296,512
|
1,352,499
|
_
|
About Impax Laboratories, Inc. (NASDAQ:IPXL)
Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches. Impax Laboratories, Inc. (NASDAQ:IPXL) Recent Trading Information
Impax Laboratories, Inc. (NASDAQ:IPXL) closed its last trading session down -0.30 at 16.10 with 1,448,637 shares trading hands.
